Phase 4 N=172 Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
Lupus Erythematosus, Systemic
Primary: Physician's Global Assessment (PGA) — 58.8; 60.6; 33.2; 30.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
Phase 4 N=38 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks — 3; 4 Participants
Phase 2 N=67 Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) — -0.26; -0.96; -0.86; -0.87 10^9 cells/L — p=0.39
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 2 N=346 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Lupus
Primary: Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169 — 59.4; 63.2; 57.4; 58.6 Percentage of participants — p=0.9745
Phase 2 N=102 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…
Phase 2 N=76 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Phase 3 N=112 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…
Phase 3 N=87 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Sclerosis, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -1.22; -3.92 unit on a scale — p=0.0915
N/A N=38 Local and Systemic Antimicrobials in Non-surgical Periodontal Therapy
Periodontitis
Primary: Change in Pocket Probing Depth (PPD) — 3.932; 4.082; 3.253; 3.294 mm
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=9 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Phase 3 N=365 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Active Systemic Lupus Erythematosus
Primary: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 — 86; 57 Participants — p=0.0013
Phase 2 N=158 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline — 45; 71 days to flare — p=0.2738
Phase 2 N=427 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score — -3.2; -3.41; -2.84; -4.04 score on a scale — p=0.4749
Phase 3 N=457 Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Active Systemic Lupus Erythematosus
Primary: Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)…
Phase 2 N=25 Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematopoietic Engraftment — 17.9 days
N/A N=139 Automatic Control of Total Intravenous Anesthesia (ACTIVA)
Anesthesia
Primary: Depth of Hypnosis Adequacy — 79.4; 16.2 percentage of maintenance duration
N/A N=60 Increasing Activity Post-Kidney Transplant With SystemCHANGE
Kidney Transplant; Complications · Physical Activity · Cardiorenal; Change
Primary: Steps Taken Per Day by Using an Activity Tracker — 4710; 5708; 4157; 4981 average of steps per day
Phase 2 N=14 Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 39.05 ng/mL
Phase 2 N=29 Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 79.85 ng/mL
Phase 2 N=183 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
Systemic Lupus Erythematosus
Primary: Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare — 94; 47 Participants
Phase 2 N=3 Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
N/A N=123 The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
Peripheral Vascular Disease
Primary: Major Adverse Events (MAE), Measured as Device and/or Procedure Related Death, Target Limb Loss and/or Clinically Driven Target Lesion Revascularization (TLR) or Target…
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
N/A N=446 The ACTIVE Intervention to Improve Hospice Care
Pain
Primary: Caregiver Perceptions of Pain Medicine Questionaire — 49.6; 49; 50.3; 50.5 units on a scale — p=.18
Phase 2 N=21 Scleroderma Treatment With Autologous Transplant (STAT) Study
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 2 N=307 A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169 — 17.6…